Galapagos NV: Galapagos presented encouraging initial safety and efficacy data at 2023 EBMT-EHA for point-of-care manufactured CAR-T candidate, GLPG5201, in rrCLL

All 7 out of 7 eligible patients with relapsed/refractory Chronic Lymphocytic Leukemia, with or without Richter's transformation, responded to treatment (Objective Response Rate of 100%)GLPG5201 showed

Related Keywords

Mechelen ,Region Flamande ,Belgium ,Japan ,Julio Delgado ,Mercedes Montoro ,Leticia Alserawan ,Valentin Ortiz Maldonado ,Christian Jacques ,Schwierige Zeiten ,Paul Stoffels ,Van Gijsel ,Sandra Cauwenberghs ,Nuria Martinez Cibrian ,Marieke Vermeersch ,Margotj Pont ,Daniel Estban ,Sergi Betriu ,Elisa Chenailler ,Exchange Commission ,European Society For Blood ,Twitter ,European Hematology Association ,Chronic Lymphocytic Leukemia ,Objective Response Rate ,European Society ,Marrow Transplantation ,Small Lymphocytic Lymphoma ,Clinical Results ,Maike Spoon ,Bayesian Optimal Interval ,Lymphocytic Leukemia ,Small Lymphocytic Leukemia ,B Cell Non Hodgkin ,Cancer Journal ,Galapagos ,Resented ,Ncouraging ,Nitial ,Safety ,Efficacy ,Data ,023 ,Bmt ,Joint ,Mare ,Manufactured ,Candidate ,Lpg5201 ,Rcll ,